Nanomedicine and Drug Delivery

Medical Clinics of North America

Volumn 91, Issue 5, 2007, Pages 863-870

  Wei, Chiming ^a   Wei, Wenchi ^a   Morris, Michael ^a   Kondo, Eisaku ^b   Gorbounov, Mikhail ^b   Tomalia, Donald A ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c Dendritic NanoTechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; DENDRIMER; NANOPARTICLE; PACLITAXEL; PEPTIDE;

ANTINEOPLASTIC ACTIVITY; BIOLOGY; BIOSENSOR; BONE TURNOVER; COLON CANCER; COMPREHENSION; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; GROWTH INHIBITION; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; IMPEDANCE; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAGNETISM; MELANOMA; MONITORING; MULTIPLE MYELOMA; NANOMEDICINE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; VASCULAR DISEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS;

EID: 34548402132     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.05.005     Document Type: Review

References (22)

1. Bosland M.C., Dreef-Van Der Meulen H.C., Sukumar S., et al. Multistage prostate carcinogenesis: the role of hormones. Princess Takamatsu Symp 22 (1991) 109-123
2. Caplan A., and Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 117 Suppl (2002) S104-S108
3. Garzotto M., Park Y., Mongoue-Tchokote S., et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 104 (2005) 1911-1917
4. Gleave M., and Evans C.P. What's hot in the prostate?. Prostate Cancer Prostatic Dis 6 (2003) 200-203
5. Gade T.P., Hassen W., Santos E., et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65 (2005) 9080-9088
6. Bucur O., Ray S., Bucur M.C., et al. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11 (2006) 1549-1568
7. Wolf S., Mertens D., Pscherer A., et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 118 (2006) 1831-1835
8. Carraway R.E., Hassan S., and Cochrane D.E. Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells. J Pharmacol Exp Ther 309 (2004) 92-101
9. Bondi M.L., Craparo E.F., Giammona G., et al. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv 14 (2007) 61-67
10. Sahoo S.K., Ma W., and Labhasetwar V. Related Articles, Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112 (2004) 335-340
11. Svenson S., and Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev (2005)
12. Tomalia D.A., Reyna L.A., and Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 35 (2007) 61-67
13. Tomalia D.A. Supramolecular chemistry: fluorine makes a difference. Nat Mater 2 (2003) 711-712
14. Svenson S., and Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 57 15 (2005) 2106-2129
15. Tomalia D.A., Reyna L.A., and Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 35 1 (2007) 61-67
16. Kondo E., Seto M., Yoshikawa K., et al. Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol Cancer Ther 3 (2004) 1623-1630
17. Patent #3748561 (E. Kondo et al.), Japan Patent Office.
18. Kolodgie F.D., Petrov A., Virmani R., et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108 (2003) 3134-3139
19. Elder A.C., Gelein R., Oberdorster G., et al. Efficient depletion of alveolar macrophages using intratracheally inhaled aerosols of liposome-encapsulated clodronate. Exp Lung Res 30 (2004) 105-120
20. Kolodgie F.D., John M., Khurana C., et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106 (2002) 1195-1198
21. Hsieh P.C., MacGillivray C., Gannon J., et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114 (2006) 637-644
22. Muro S., Cui X., Gajewski C., et al. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 285 (2003) C1339-C1347